By Iain Davis, UK Column: We appear to have serious problems with the Covid-19 vaccination programme. The evidence underpinning the claimed efficacy and safety of the Pfizer BNT162b2 vaccine is highly questionable. Statistical analysis raises numerous issues, and until these are addressed, the alleged benefits cannot be shown to outweigh the risks.
With wider concerns expressed by some of the world’s leading immunologists, virologists and epidemiologists, justification for the continued vaccination programme appears to be lacking. Possible unacceptable risk is evident in every nation which has vaccinated a significant proportion of its population.
The vaccines appear to increase the mortality risk from Covid-19, something the authorities and the regulatory agencies have so far shown little or no interest in investigating.
Some of what we are about to discuss is necessarily speculative. It is based upon a full statistical analysis—but, absent a comprehensive investigation, we cannot be certain why this analysis appears to show an increased Covid-19 mortality risk following vaccination.
Equally, refusal to investigate this correlation is untenable. No claim of either vaccine safety or efficacy is justified without properly accounting for this statistical analysis.
Concerning Data Emerges in Israel
Recently, the UK Column interviewed, among others, Dr Hervé Seligmann (Part 1 here). Dr Seligmann has a B.Sc. in Biology from the Hebrew University of Jerusalem. He earned an M.Sc. in 1991 and gained his Ph.D in 2003. He has had over 100 scientific papers published. He works at the Emerging Infectious and Tropical Diseases Research Unit, Faculty of Medicine, Aix-Marseille University, Marseilles, France. His statistical research partner is the engineer Haim Yativ.
Dr Seligmann and Mr Yativ have posted an informative English-language resource pagewhere you can see recent updates to their research. Their analysis of Israeli data appears to show a significant increased risk of Covid-19 mortality (for the vaccinated) during the period between receipt of the first and second vaccine doses, and for a brief period following the second dose. Their research has focused upon the Pfizer/BioNTech BNT162b2 vaccine (tozinameran).
Read the full story here.